Table 2 Examples of NRG1 fusions, their frequency, and partners, in various cancers (see also Fig. 2)

All cancers

0.15–0.5%

Multiple—see below

[54]

Non-small cell lung cancer

0.3–0.8%

CD74

SDC4

SLC3A2

TNC

MDK

ATP1B1

DIP2B

RBPMS

MRPL13

ROCK1

DPYSL2

PARP8

[54,55,56]

Gallbladder

0.5%

NOTCH2

ATP1B1

[54]

Pancreatic ductal adenocarcinoma

0.5–1.2%

ATP1B1

CDH1

VTCN1

[54,55,56]

Renal cell carcinoma

0.5%

RBPMS

[54, 55]

Ovarian

0.4%

SETD4

TSHZ2

ZMYM2

[54, 55]

Breast

0.2–0.5%

ADAM9

COX10-AS1

[54,55,56]

Sarcoma

0.2%

WHSC1L1

[54, 55]

Bladder

0.1%

GDF15

[54, 55]

Colorectal

0.1%

POMK

[54, 55]

NRG1 fusion partners and their relative frequency across cancers

Fusion partner with NRG1

Frequency of fusion partner

References

CD74

29–31%

[29, 54, 57, 58]

ATP1B1

10%

[23, 54, 59]

SDC4

7–11%

[54, 57]

RBPMS

2–5%

[54, 57, 59]

ADAM9

2%

[54, 59, 60]

CDH1

2%

[54, 60]

COX10-AS1

2%

[54, 60]

GDF15

2%

[54]

NOTCH2

2%

[54, 60]

POMK

2%

[54, 60]

SETD4

2%

[54, 60]

SLC3A2

2%

[29, 54, 59]

TSHZ2

2%

[54, 60]

VTCN1

2%

[54, 60]

WHSC1L1

2%

[54, 60]

ZMYM2

2%

[54, 60]

ROCK1

1–2%

[54, 59, 60]

MDK

1–2%

[54, 60]

MRPL13

1–2%

[54, 59, 60]

TNC

1–2%

[54, 59, 60]

DIP2B

1–2%

[54, 60]

PARP8

1–2%

[54, 59, 60]

DPYSL2

1–2%

[54, 59, 60]